Capnia (CAPN) Reports Q1 Loss of $0.22 per Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St to open lower as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Oppenheimer sees AI software winners as focus shifts to ROI
- Nvidia releases AI safety software it says could have stopped Hugging Face hack
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
Capnia Reports First Quarter 2016 Financial Results
May 10, 2016 9:29 AM EDTREDWOOD CITY, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ: CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced financial results for the first quarter ended March 31, 2016.
During early 2016, we made significant progress advancing both our commercial product portfolio as well as our therapeutics pipeline, said Anish Bhatnagar, M.D., Chief Executive Officer of Capnia. We signed two important distribution agreements for CoSense in the US and China, and commenced sales of Serenz Allergy Relief to pharmacies... More
